July 16, 2021
(Reuters) – Britain’s GlaxoSmithKline on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising 400 million pounds ($552.76 million) through the sale of some land at the facility.
The drugmaker said it expects to select a developer from the private sector later this year, and will begin work on the project in 2022.
($1 = 0.7236 pounds)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shailesh Kuber)